Statins and diabetes - Indications and reimbursement rules;Statiner og diabetes - Indikasjoner og refusjonsregler

Tidsskrift for den Norske Laegeforening

Volumn 123, Issue 11, 2003, Pages 1564-1565

  Claudi, Tor ^a   Birkeland, Kåre ^b   Jensen, Trond ^c  

^a Rønvik Legesenter   (Norway)

^b AKER UNIVERSITY HOSPITAL   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; RAMIPRIL; HYPOCHOLESTEROLEMIC AGENT;

ADULT; AGED; CARDIOVASCULAR RISK; DIABETES MELLITUS; DRUG INDICATION; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; REIMBURSEMENT; SHORT SURVEY; ARTICLE; CARDIOVASCULAR DISEASE; PATIENT ABANDONMENT; PRACTICE GUIDELINE; RISK FACTOR;

ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; PRACTICE GUIDELINES; REFUSAL TO TREAT; RISK FACTORS;

EID: 0242305131     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (14)

1. Terapianbefaling: behandling av hyperlipidemi. SLK-publikasjon 2000: 6. Oslo: Statens legemid-delkontroll, 2000.
2. Birkeland KI, Claudi T, Hansteen V, Hanssen KF, Hjermann I, Jenssen T et al. Forebygging av hjerte- og karsykdom hos pasienter med type 2-diabetes. Tidsskr Nor Lægeforen 2000; 120: 2554-9.
3. Claudi T, Cooper JG, Midthjell K, Daae C, Furuseth K, Hanssen KF. NSAMs handlingsprogram for diabetes i allmennpraksis, Skriftserie for leger: Utdanning og kvalitetssikring. Oslo: Norsk selskap for allmennmedisin, Den norske lægeforening, Norges Diabetesforbund, Statens institutt for folkehelse, 2000.
4. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-34.
5. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998; 316: 823-8.
6. Evans JMM, Wang J, Morris AD. Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies. BMJ 2002; 324: 939-42.
7. Chae CU, Ajani UA, Moreno-John G, Buring JE, Manson JE. Diabetes and all-cause and coronary heart disease mortality among US male physicians. Arch Intern Med 2001; 161: 242-7.
8. Hu FB, Stampfer MJ, Solomon CG, Liu S, Willett WC, Speizer FE et al. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women. 20 years of follow-up. Arch Intern Med 2001; 161: 1717-23.
9. Pyörälä K, Pedersen TR, Kjekshus J, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997; 20: 614-20.
10. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57.
11. The CARE Investigators. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial survivors with average cholesterol levels: subgroup analysis in the cholesterol and recurrent events (CARE) trial. Circuation 1998; 98: 2513-9.
12. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin an 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
13. Tonstad S, Holme I. Videre belysning av statinbe-handling: Heart Protection Study. Tidsskr Nor Lægeforen 2002; 122: 277-80.
14. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-53.